Overview

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer. Patients will be treated until disease progression or until the investigator has determined that treatment is not in the best interest of the patient, whichever occurs first.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Estradiol
Exemestane
Fulvestrant
Hormones